Blueprint Medicines Corp. Forecast, price target & analysts
Blueprint Medicines Corp. Target price 2025 - Analyst rating & recommendation
Blueprint Medicines Corp. Classifications & Recommendation:
Blueprint Medicines Corp. Price Target
| Target Price | $126.10 |
| Price | $101.84 |
| Potential |
23.82%
register free of charge
|
| Number of Estimates | 21 |
|
21 Analysts have issued a price target Blueprint Medicines Corp. 2026 .
The average Blueprint Medicines Corp. target price is $126.10.
This is
23.82%
register free of charge
$167.00
63.99%
register free of charge
$83.00
18.50%
register free of charge
|
|
| A rating was issued by 23 analysts: 17 Analysts recommend Blueprint Medicines Corp. to buy, 5 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Blueprint Medicines Corp. stock has an average upside potential 2026 of
23.82%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 508.82 | 721.76 |
| 104.03% | 41.85% | |
| EBITDA Margin | -38.47% | -6.42% |
| 79.79% | 83.31% | |
| Net Margin | -13.58% | -7.12% |
| 93.73% | 47.56% |
21 Analysts have issued a sales forecast Blueprint Medicines Corp. 2025 . The average Blueprint Medicines Corp. sales estimate is
This results in the following potential growth metrics:
5 Analysts have issued an Blueprint Medicines Corp. EBITDA forecast 2025. The average Blueprint Medicines Corp. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
21 Blueprint Medicines Corp. Analysts have issued a net profit forecast 2025. The average Blueprint Medicines Corp. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -1.07 | -0.80 |
| 87.22% | 25.23% | |
| P/E | negative | |
| EV/Sales | 9.30 |
21 Analysts have issued a Blueprint Medicines Corp. forecast for earnings per share. The average Blueprint Medicines Corp. EPS is
This results in the following potential growth metrics and future valuations:
Blueprint Medicines Corp....
Current Blueprint Medicines Corp. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | May 02 2025 |
| Needham |
Locked
➜
Locked
|
Locked | Apr 28 2025 |
| Wedbush |
Locked
➜
Locked
|
Locked | Apr 16 2025 |
| Needham |
Locked
➜
Locked
|
Locked | Apr 08 2025 |
| Jefferies |
Locked
➜
Locked
|
Locked | Mar 17 2025 |
| Scotiabank |
Locked
➜
Locked
|
Locked | Mar 07 2025 |
| Citizens Capital Markets |
Locked
➜
Locked
|
Locked | Mar 03 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
May 02 2025 |
|
Locked
Needham:
Locked
➜
Locked
|
Apr 28 2025 |
|
Locked
Wedbush:
Locked
➜
Locked
|
Apr 16 2025 |
|
Locked
Needham:
Locked
➜
Locked
|
Apr 08 2025 |
|
Locked
Jefferies:
Locked
➜
Locked
|
Mar 17 2025 |
|
Locked
Scotiabank:
Locked
➜
Locked
|
Mar 07 2025 |
|
Locked
Citizens Capital Markets:
Locked
➜
Locked
|
Mar 03 2025 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
